Loading…
Based on limited metadata, Akorn Inc. received an FDA Warning Letter in June 2019 regarding drug manufacturing or quality control issues, though the specific violations cannot be detailed without access to the full letter text. The warning falls under FDA's drug product regulatory jurisdiction, indicating concerns likely related to manufacturing practices, product quality, or compliance with pharmaceutical regulations. Without the complete letter subject line and violation details, the precise nature of the compliance failures cannot be specified beyond confirming they involve the company's drug products or operations.